Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands-A review

Journal of Psychiatric Research

Volumn 70, Issue , 2015, Pages 50-57

  Jongkees, Bryant J ^a   Hommel, Bernhard ^a   Kühn, Simone ^b   Colzato, Lorenza S ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MAX PLANCK INSTITUTE FOR HUMAN DEVELOPMENT   (Germany)

Author keywords

Cognition; Dopamine; Mood; Norepinephrine; Stress; Tyrosine

Indexed keywords

CATECHOLAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NORADRENALIN; PHENYLALANINE; PLACEBO; SEROTONIN; TYROSINE;

ALERTNESS; ATTENTION; CATECHOLAMINE DEPLETION; COGNITION; COLD CLIMATE; COLD EXPOSURE; CORPUS STRIATUM; DEPRESSION; ENDURANCE; EVENT RELATED POTENTIAL; EXECUTIVE FUNCTION; EXERCISE; EYE TRACKING; HYPOTHERMIA; LOCUS CERULEUS; MEMORY TEST; MOTIVATION; NEGATIVE SYNDROME; PARKINSON DISEASE; PHENYLKETONURIA; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SCHIZOPHRENIA; SLEEP DEPRIVATION; STRESS; STROOP TEST; SUPPLEMENTATION; SYSTEMATIC REVIEW; THERMAL EXPOSURE; THINKING; WISCONSIN CARD SORTING TEST; WORKING MEMORY; ANIMAL; COGNITIVE DEFECT; DIET THERAPY; DIETARY SUPPLEMENT; HUMAN; MENTAL STRESS; PSYCHOLOGY;

ANIMALS; COGNITION; COGNITION DISORDERS; DIETARY SUPPLEMENTS; HUMANS; STRESS, PSYCHOLOGICAL; TYROSINE;

EID: 84943389085     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.08.014     Document Type: Review

References (94)

1. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 2003, 23:2008-2013.
2. Baddeley A.D., Hitch G. Working memory. The Psychology of Learning and Motivation: Advances in Research and Theory 1974, 47-89. Academic Press, New York. G.H. Bower (Ed.).
3. Banderet L.E., Lieberman H.R. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental-stress in humans. Brain Res. Bull. 1989, 22:759-762.
4. Barch D.M., Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr. Res. 2005, 77:43-58.
5. Bongiovanni R., Leonard S., Jaskiw G.E. A simplified method to quantify dysregulated tyrosine transport in schizophrenia. Schizophr. Res. 2013, 150:386-391.
6. Brodnik Z., Bongiovanni R., Double M., Jaskiw G.E. Increased tyrosine availability increases brain regional DOPA levels in vivo. Neurochem. Int. 2012, 61:1001-1006.
7. Chinevere T.D., Sawyer R.D., Creer A.R., Conlee R.K., Parcell A.C. Effects of L-tyrosine and carbohydrate ingestion on endurance exercise performance. J. Appl. Physiol. 2002, 93:1590-1597.
8. Colzato L.S., De Haan A., Hommel B. Food for creativity: tyrosine promotes performance in a convergent-thinking task. Psychol. Res. 2014, 79:709-714.
9. Colzato L.S., Jongkees B.J., Sellaro R., Hommel B. Working memory reloaded: tyrosine repletes updating in the N-back task. Front. Behav. Neurosci. 2013, 7:200.
10. Colzato L.S., Jongkees B.J., van den Wildenberg W.P.M., Hommel B. Eating to stop: tyrosine supplementation enhances inhibitory control but not response execution. Neuropsychologia 2014, 62:398-402.
11. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2011, 69:e113-e125.
12. Cools R., Gibbs S.E., Miyakawa A., Jagust W., D'Esposito M. Working memory capacity predicts dopamine synthesis capacity in the human striatum. J. Neurosci. 2008, 28:1208-1212.
13. Cuche J.L., Prinseau J., Selz F., Ruget G., Tual J.L., Reingeissen L., et al. Oral load of tyrosine or l-dopa and plasma levels of free and sulfoconjugated catecholamines in healthy men. Hypertension 1985, 7:81-89.
14. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 1991, 11:1907-1917.
15. Daubner S.C., Le T., Wang S.Z. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 2011, 508:1-12.
16. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
17. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1471-1486.
18. Deijen J.B. Tyrosine. Nutrition Brain and Behavior 2005, 363-381. CRC Press, Boca Raton. H.R. Lieberman, R.B. Kanarek, J.F. Orbleke (Eds.).
19. Deijen J.B., Orbleke J.F. Effect of tyrosine on cognitive function and blood-pressure under stress. Brain Res. Bull. 1994, 33:319-323.
20. Deijen J.B., Wientjes C.J.E., Vullinghs H.F.M., Cloin P.A., Langefeld J.J. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Res. Bull. 1999, 48:203-209.
21. Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2011, 69:E145-E157.
22. Deutsch S.I., Rosse R.B., Schwartz B.L., Banay-Schwartz M., McCarthy M.F., Johri S.K. L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin. Neuropharmacol. 1994, 17:53-62.
23. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
24. Eisenberg J., Asnis G.M., Van Praag H.M., Vela R.M. Effect of tyrosine on attention deficit disorder with hyperactivity. J. Clin. Psychiatry 1988, 49:193-195.
25. Fernstrom J.D. Aromatic amino acids and monoamine synthesis in the central nervous system: influence of the diet. J. Nurt. Biochem. 1990, 1:508-517.
26. Fernstrom J.D. Can nutrient supplements modify brain function?. Am. J. Clin. Nutr. 2000, 71:1669S-1673S.
27. Fernstrom J.D., Fernstrom M.H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 2007, 137:1539S-1547S.
28. Finlay J.M. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr. Bull. 2001, 27:431-442.
29. Foster H.D., Hoffer A. The two faces of l-DOPA: benefits and adverse side effects in the treatment of encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis. Med. Hypotheses 2004, 62:177-181.
30. Gelenberg A.J., Gibson C.J. Tyrosine for the treatment of depression. Nutr. Health 1984, 3:163-173.
31. Gelenberg A.J., Wojcik J.D., Falk W.E., Baldessarini R.J., Zeisel S.H., Schoenfeld D., et al. Tyrosine for depression: a double-blind trial. J. Affect. Disord. 1990, 19:125-132.
32. Gelenberg A.J., Wojcik J.D., Growdon J.H., Sved A.F., Wurtman R.J. Tyrosine for the treatment of depression. Am. J. Psychiatry 1980, 137:622-623.
33. Gibson C.J., Wurtman R.J. Physiological control of brain catechol synthesis by brain tyrosine concentration. Biochem. Pharmacol. 1977, 26:1137-1142.
34. Glaeser B.S., Melamed E., Growdon J.H., Wurtman R.J. Elevation of plasma tyrosine after a single oral dose of l-tyrosine. Life Sci. 1979, 25:265-271.
35. Goldberg I.K. L-tyrosine in depression. Lancet 1980, 2:364-365.
36. Goldman-Rakic P.S., Muly E.C., Williams G.V. D1 receptors in prefrontal cells and circuits. Brain Res. Rev. 2000, 31:295-301.
37. Growdon J.H., Melamed E., Logue M., Hefti F., Wurtman R.J. Effects of oral l-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sci. 1982, 30:827-832.
38. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
39. Hanley W.B., Lee A.W., Hanley A.J.G., Lehotay D.C., Austin V.J., Schoonheyt W.E., et al. "Hypotyrosinemia" in phenylketonuria. Mol. Genet. Metab. 2000, 69:286-294.
40. Harald B., Gordon P. Meta-review of depressive subtyping models. J. Affect. Disord. 2012, 139:126-140.
41. Howes O., McCutcheon R., Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacol. 2015, 29:97-115.
42. Jongkees B.J., Hommel B., Colzato L.S. People are different: tyrosine's modulating effect on cognitive control in healthy humans may depend on individual differences related to dopamine function. Front. Psychol. 2014, 5:1101.
43. Kalsner L.R., Rohr F.J., Strauss K.A., Korson M.S., Levy H.L. Tyrosine supplementation in phenylketonuria: diurnal blood tyrosine levels and presumptive brain influx of tyrosine and other large neutral amino acids. J. Pediatr. 2001, 139:421-427.
44. Kaufman S., Friedman S. Dopamine-beta-hydroxylase. Pharmacol. Rev. 1965, 17:71-100.
45. Kishore K., Ray K., Anand J.P., Thakur L., Kumar S., Panjwani U. Tyrosine ameliorates heat induced delay in event related potential P300 and contingent negative variation. Brain Cognit. 2013, 83:324-329.
46. Kvetnansky R., Sabban E.L., Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol. Rev. 2009, 89:535-606.
47. Leathwood P.D., Pollet P. Diet-induced mood changes in normal-populations. J. Psychiatr. Res. 1983, 17:147-154.
48. Lehnert H., Reinstein D.K., Strowbridge B.W., Wurtman R.J. Neurochemical and behavioral consequences of acute uncontrollable stress: effects of dietary tyrosine. Brain Res. 1984, 303:215-223.
49. Lemoine P., Robelin N., Sebert P., Mouret J. L-tyrosine: a long term treatment of Parkinson's disease. C. R. Acad. Sci. III 1989, 309:43-47.
50. Lieberman H.R., Corkin S., Spring B.J., Growdon J.H., Wurtman R.J. Mood, performance, and pain sensitivity - changes induced by food constituents. J. Psychiatr. Res. 1983, 17:135-145.
51. Lieberman H.R., Georgelis J.H., Maher T.J., Yeghiayan S.K. Tyrosine prevents effects of hyperthermia on behavior and increases norepinephrine. Physiol. Behav. 2005, 84:33-38.
52. Lieberman H.R., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987, 91:415-433.
53. Liggins J., Pihl R.O., Benkelfat C., Leyton M. The dopamine augmenter l-DOPA does not affect positive mood in healthy human volunteers. PLoS One 2012, 7:e28370.
54. Magill R.A., Waters W.F., Bray G.A., Volaufova J., Smith S.R., Lieberman H.R., et al. Effects of tyrosine, phentermine, caffeine d-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation. Nutr. Neurosci. 2003, 6:237-246.
55. Mahoney C.R., Castellani J., Kramer F.M., Young A., Lieberman H.R. Tyrosine supplementation mitigates memory decrements during cold exposure. Physiol. Behav. 2007, 92:575-582.
56. McConnel H. Catecholamine metabolism in the attention deficit disorder - implications for the use of amino-acid precursor therapy. Med. Hypotheses 1985, 17:305-311.
57. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 2005, 8:594-596.
58. Miyake A., Friedman N.P., Emerson M.J., Witzki A.H., Howerter A., Wager T.D. The unity and diversity of executive functions and their contributions to complex "frontal lobe" tasks: a latent variable analysis. Cogn. Psychol. 2000, 41:49-100.
59. Moustafa A.A., Sherman S.J., Frank M.J. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Neuropsychologia 2008, 46:3144-3156.
60. Muly E.C., Szigeti K., Goldman-Rakic P.S. D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. J. Neurosci. 1998, 18:10553-10565.
61. Nemzer E.D., Arnold L.E., Votolato N.A., McConnell H. Amino-acid supplementation as therapy for attention-deficit disorder. J. Am. Acad. Child. Psychiatry 1986, 25:509-513.
62. Nieuwenhuis S., Aston-Jones G., Cohen J.D. Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol. Bull. 2005, 131:510-532.
63. O'Brien C., Mahoney C., Tharion W.J., Sils I.V., Castellani J.W. Dietary tyrosine benefits cognitive and psychomotor performance during body cooling. Physiol. Behav. 2007, 90:301-307.
64. Palinkas L.A., Reedy K.R., Smith M., Anghel M., Steel G.D., Reeves D., et al. Psychoneuroendocrine effects of combined thyroxine and triiodothyronine versus tyrosine during prolonged antarctic residence. Int. J. Circumpol. Heal 2007, 66:401-417.
65. Parker G., Brotchie H. Mood effects of the amino acids tryptophan and tyrosine. Acta Psychiat. Scand. 2011, 124:417-426.
66. Pellow J., Solomon E.M., Barnhard C.N. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern. Med. Rev. 2011, 16:323-337.
67. Pietz J., Landwehr R., Kutscha A., Schmidt H., De Sonneville L., Trefz F.K. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. J. Pediatr. 1995, 127:936-943.
68. Pollin W., Cardon P.V., Kety S.S. Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 1961, 133:104-105.
69. Posner J., Gorman D., Nagel B.J. Tyrosine supplements for ADHD symptoms with comorbid phenylketonuria. J. Neuropsych. Clin. N. 2009, 21:228-230.
70. Rauch T.M., Lieberman H.R. Tyrosine pretreatment reverses hypothermia-induced behavioral depression. Brain Res. Bull. 1990, 24:147-150.
71. Reimherr F.W., Wender P.H., Wood D.R., Ward M. An open trial of l-tyrosine in the treatment of attention-deficit disorder, residual type. Am. J. Psychiatry 1987, 144:1071-1073.
72. Sapru M.K., Rao B.S.S.R., Channabasavanna S.M. Serum dopamine-beta-hydroxylase activity in clinical subtypes of depression. Acta Psychiat. Scand. 1989, 80:474-478.
73. Seeman P. Schizophrenia and dopamine receptors. Eur. Neuropsychopharmacol. 2013, 23:999-1009.
74. Shurtleff D., Thomas J.R., Ahlers S.T., Schrot J. Tyrosine ameliorates a cold-induced delayed matching-to-sample performance decrement in rats. Psychopharmacology 1993, 112:228-232.
75. Shurtleff D., Thomas J.R., Schrot J., Kowalski K., Harford R. Tyrosine reverses a cold-induced working-memory deficit in humans. Pharmacol. Biochem. Behav. 1994, 47:935-941.
76. Siessmeier T., Kienast T., Wrase J., Larsen J.L., Braus D.F., Smolka M.N., et al. Net influx of plasma 6-[F-18]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur. J. Neurosci. 2006, 24:305-313.
77. Slifstein M., Van de Giessen E., Van Snellenberg J., Thompson J.L., Narendran R., Gil R., et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015, 72:316-324.
78. Smith M.L., Hanley W.B., Clarke J.T.R., Klim P., Schoonheyt W., Austin V., et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch. Dis. Child. 1998, 78:116-121.
79. Steenbergen L., Sellaro R., Hommel B., Colzato L.S. Tyrosine promotes cognitive flexibility: evidence from proactive vs. reactive control during task switching performance. Neuropsychologia 2015, 69:50-55.
80. Sutton E.E., Coill M.R., Deuster P.A. Ingestion of tyrosine: effects on endurance, muscle strength, and anaerobic performance. Int. J. Sport. Nutr. Exerc 2005, 15:173-185.
81. Tam S.Y., Elsworth J.D., Bradberry C.W., Roth R.H. Mesocortical dopamine neurons: high basal firing frequency predicts tyrosine dependence of dopamine synthesis. J. Neural Transm. 1990, 81:97-110.
82. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008, 102:1-18.
83. Thomas J.R., Lockwood P.A., Singh A., Deuster P.A. Tyrosine improves working memory in a multitasking environment. Pharmacol. Biochem. Behav. 1999, 64:495-500.
84. Tumilty L., Davison G., Beckmann M., Thatcher R. Failure of oral tyrosine supplementation to improve exercise performance in the heat. Med. Sci. Sports Exerc 2014, 46:1417-1425.
85. Tumilty L., Davison G., Beckmann M., Thatcher R. Oral tyrosine supplementation improves exercise capacity in the heat. Eur. J. Appl. Physiol. 2011, 111:2941-2950.
86. Van Spronsen F.J., De Groot M.J., Hoeksma M., Reijngoud D.J., Van Rijn M. Large neutral amino acids in the treatment of PKU: from theory to practice. J. Inherit. Metab. Dis. 2010, 33:671-676.
87. Van Spronsen F.J., Van Rijn M., Bekhof J., Koch R., Smit P.G.A. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. Am. J. Clin. Nutr. 2001, 73:153-157.
88. Watson P., Enever S., Page A., Stockwell J., Maughan R.J. Tyrosine supplementation does not influence the capacity to perform prolonged exercise in a warm environment. Int. J. Sport. Nutr. Exerc 2012, 22:363-373.
89. Wiesel F.A., Andersson J.L.R., Westerberg G., Wieselgren I.M., Bjerkenstedt L., Hagenfeldt L., et al. Tyrosine transport is regulated differently in patients with schizophrenia. Schizophr. Res. 1999, 40:37-42.
90. Wiesel F.A., Edman G., Flyckt L., Eriksson A., Nyman H., Venizelos N., et al. Kinetics of tyrosine transport and cognitive functioning in schizophrenia. Schizophr. Res. 2005, 74:81-89.
91. Wood D.R., Reimherr F.W., Wender P.H. Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol. Bull. 1985, 21:146-149.
92. Wurtman R.J., Hefti F., Melamed E. Precursor control of neurotransmitter synthesis. Pharmacol. Rev. 1981, 32:315-335.
93. Yeghiayan S.K., Luo S.Q., Shukitt-Hale B., Lieberman H.R. Tyrosine improves behavioral and neurochemical deficits caused by cold exposure. Physiol. Behav. 2001, 72:311-316.
94. Zhu Y.Z., Zhang J., Zeng Y.J. Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol. Disord. Drug Targets 2012, 11:350-358.